Materials and methods for treatment of human genetic diseases including hemoglobinopathies
The present application provides materials and methods for treating hemoglobinopathies. More specifically, the application provides methods for producing progenitor cells that are genetically modified via genome editing to increase the production of fetal hemoglobin (HbF), as well as modified progenitor cells (including, for example, CD34 + human hematopoietic stem cells) producing increased levels of HbF, and methods of using such cells for treating hemoglobinopathies such as sickle cell anemia and β-thalassemia.
1. A method of gene editing, the method comprising introducing Cas9 endonuclease, a first guide RNA (gRNA), and a second gRNA into a human cell to effect a pair of double-strand breaks (DSBs) within the δβ-globin region of human chromosome 11, wherein the first gRNA comprises a spacer sequence that hybridizes to the same target sequence of the δβ-globin region of human chromosome 11 as a nucleic acid having the nucleic acid sequence of any one of SEQ ID NO: 1-117 and 129-137, the second gRNA comprises a spacer sequence that hybridizes to the same target sequence of the δβ-globin region of human chromosome 11 as a nucleic acid having the nucleic acid sequence of any one of SEQ ID NO: 1-117 and 129-137, and wherein the first gRNA hybridizes to a different target sequence than the second gRNA.
2. The method of claim 1 , wherein the method comprises introducing into the cell one or more polynucleotides encoding the Cas9 endonuclease.
3. The method of claim 1 , wherein the method comprises introducing into the cell one or more RNAs encoding the Cas9 endonuclease.
4. The method of claim 3 , wherein the one or more RNAs are modified RNAs.
5. The method of claim 1 , wherein the first gRNA and/or the second gRNA are single-molecule gRNAs (sgRNAs).
6. The method of claim 1 , wherein the human cell is an isolated progenitor cell.
7. The method of claim 6 , wherein the isolated progenitor cell is a hematopoietic progenitor cell.
8. The method of claim 7 , wherein the hematopoietic progenitor cell is capable of giving rise to cells of the erythroid lineage.
9. The method of claim 1 , wherein there is a deletion of the chromosomal DNA between the pair of DSBs within the δβ-globin region of human chromosome 11.
10. The method of claim 1 , wherein the human cell is from a patient with a β-hemoglobinopathy which is a sickle cell disease or a β-thalassemia.
11. The method of claim 10 , wherein the β-hemoglobinopathy is sickle cell disease.
12. The method of claim 10 , wherein the β-hemoglobinopathy is a β-thalassemia.
13. The method of claim 1 , wherein:
(a) the first gRNA comprises a spacer sequence that is complementary to SEQ ID NO: 4 and the second gRNA comprises a spacer sequence that is complementary to SEQ ID NO: 19; or
(b) the first gRNA comprises a spacer sequence that is complementary to SEQ ID NO: 4 and the second gRNA comprises a spacer sequence that is complementary to SEQ ID NO: 20; or
(c) the first gRNA comprises a spacer sequence that is complementary to SEQ ID NO: 83 and the second gRNA comprises a spacer sequence that is complementary to SEQ ID NO: 43; or
(d) the first gRNA comprises a spacer sequence that is complementary to SEQ ID NO: 83 and the second gRNA comprises a spacer sequence that is complementary to SEQ ID NO: 15; or
(e) the first gRNA comprises a spacer sequence that is complementary to SEQ ID NO: 83 and the second gRNA comprises a spacer sequence that is complementary to SEQ ID NO: 43.
14. The method of claim 1 , wherein the first gRNA and/or the second gRNA comprises a spacer sequence that hybridizes to the same target sequence of the δβ-globin region of human chromosome 11 as a nucleic acid having the nucleic acid sequence of any one of SEQ ID NOs: 4, 5, 6, 15, 19, and 20.